Cell death in hematological tumors.
Evasion of apoptosis is a hallmark of human cancers, for example in hematological malignancies. Apoptosis is an intrinsic cell death program that is crucial to maintain tissue homeostasis, for example in the hematopoietic system where there is a high turnover rate of cells. As a result, a decrease in the rate of apoptosis besides an increase in proliferation favors tumorigenesis as well as tumor progression. Further, the anti-leukemic action of current treatment approaches, including chemo-, radio- or immunotherapy, critically relies on intact cell death programs in cancer cells. Therefore, defects in apoptosis pathways are frequently associated with the resistance to anticancer therapies. In recent years, the identification and characterization of the molecules and pathways that are involved in the regulation and execution of cell death in leukemia and lymphoma cells have set the ground for the development of novel diagnostic tools and molecular therapeutics targeting apoptosis pathways in hematological malignancies.
Fulda
Simone
S
University Children's Hospital, Ulm, Germany. simone.fulda@uniklinik-ulm.de
D017209:Apoptosis; D016923:Cell Death; D002471:Cell Transformation, Neoplastic; D019337:Hematologic Neoplasms / Q000473:pathology*; D006801:Humans; D007938:Leukemia / Q000473:pathology; D008223:Lymphoma / Q000473:pathology; D008954:Models, Biological; D019253:Proto-Oncogene Proteins c-bcl-2 / Q000502:physiology; D053221:TNF-Related Apoptosis-Inducing Ligand / Q000502:physiology; D051636:X-Linked Inhibitor of Apoptosis Protein / Q000502:physiology
D019253:Proto-Oncogene Proteins c-bcl-2; D053221:TNF-Related Apoptosis-Inducing Ligand; D051636:X-Linked Inhibitor of Apoptosis Protein; C496866:XIAP protein, human